Last reviewed · How we verify
Elimite
At a glance
| Generic name | Elimite |
|---|---|
| Also known as | Permethrin Cream, 5% |
| Sponsor | Mayne Pharma International Pty Ltd |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparison of Permethrin-Based Treatment Strategies Against Scabies in Infants and Young Children (EARLY_PHASE1)
- Ivermectin Safety in Small Children (PHASE2)
- Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial (PHASE1, PHASE2)
- Better Options for Lymphatic Filariasis Treatment (PHASE3)
- A Phase 3 Trial Assessing Safety and Efficacy of B-Pa-L in Participants With DR-TB (PHASE3)
- Permethrin-treated Baby-wraps for the Prevention of Malaria in Children (NA)
- Repellents as Added Control Measure to Long Lasting Insecticidal Nets (NA)
- Comparison of Permethrin and Ivermectin in Children Greater Than 6 Yrs Age for Treatment of Scabies (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Elimite CI brief — competitive landscape report
- Elimite updates RSS · CI watch RSS
- Mayne Pharma International Pty Ltd portfolio CI